Working compound and dosage | Brand name | Manufacturer | Number of different marketing authorisation holders | Steps | |||||||||||||||||
Shaking | Dust cap | Nose blowing | Hand position A | Hand position B | Closing nostril A | Closing nostril B | Head position A | Head position B | Position spray | Inhalation A | Inhalation B | Exhalation | Clean nozzle A | Clean nozzle B | Dust cap | Storage | |||||
1 | Beclomethasone 50 µg | - | Mylan | 16 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
2 | Beclomethasone 50 µg | Beconase | Omega | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
3 | Beclomethasone 50 µg | Beconase | GSK | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
4 | Beclomethasone 50 µg | Nasobec | Teva | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
5 | Beclomethasone 50 µg | Hayfever relief | Ayrton Saunders | 9 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
6 | Beclomethasone 50 µg | Pollenase | Ayrton Saunders | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
7 | Beclomethasone 50 µg | - | Ennogen Pharma | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
8 | Budesonide 64 µg | - | Sandoz | 4 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
9 | Budesonide 64 µg | Rhinocort | Astrazeneca | 4 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
10 | Budesonide 64 µg | Benacort | Astrazeneca | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
11 | Fluticasone furoate 50 µg | Pirinase hayfever relief | GSK | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||
12 | Fluticasone furoate 50 µg | Hayfever and allergy | GSK | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
13 | Fluticasone furoate 50 µg | Flixonase | GSK | 7 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||
14 | Fluticasone furoate 50 µg | Nasofan | Teva | 11 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
15 | Fluticasone furoate 50 µg | Flunase | Teva | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
16 | Azelastine 125 µg Fluticasone propionate 50 µg | Dymista | Meda Pharma | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
17 | Fluticasone proprionate 27.5 µg | Avamys | GSK | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||
18 | Mometasone furoate 50 µg | - | Teva | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
19 | Mometasone furoate 50 µg | - | Sandoz | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
20 | Mometasone furoate 50 µg | - | Schering-Plough Labo | 10 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
21 | Mometasone furoate 50 µg | - | Cipla | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Listed are the included INCS. Indicated is the working compound and dosage, the brand name if present, the manufacturer and the number of marketing authorisation holders if present. Also, illustrated is an overview of the consecutive steps for use of INCS as described in table 1. For each spray is indicated whether a specific step is supplied in the PIL , if supplied than the box is ticked with ✓.